PGNY News and Press, Progyny Inc.

2026-03-06 14:03:28 ET Brian Tanquilut from Jefferies issued a price target of $30.00 for PGNY on 2026-03-06 17:01:00. The adjusted price target was set to $30.00. At the time of the announcement, PGNY was trading at $17.7858. The overall price target consensus is at $31...

NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced that several members of its leadership team will participate in upcoming investor conferences in March, including the Leerink Partners...

2026-03-04 11:13:14 ET Introduction Progyny ( PGNY ) is being misclassified by the market. The company delivered a record year in 2025 in terms of revenue, EBITDA, and operating cash flow.... Read the full article on Seeking Alpha For further details see: Progyny...

2026-03-02 06:03:42 ET Jailendra Singh from Truist Financial issued a price target of $28.00 for PGNY on 2026-03-02 10:24:00. The adjusted price target was set to $28.00. At the time of the announcement, PGNY was trading at $17.69. The overall price target consensus is a...

2026-02-26 20:18:33 ET More on Progyny Progyny, Inc. (PGNY) Q4 2025 Earnings Call Transcript Progyny, Inc. (PGNY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Progyny, Inc. (PGNY) Presents at 44th Annual J.P. Morgan Healthcare Conference Tran...

2026-02-26 20:17:47 ET Progyny, Inc. (PGNY) Q4 2025 Earnings Call February 26, 2026 4:45 PM EST Company Participants James Hart - Vice President of Investor Relations Peter Anevski - CEO & Director Mark Livingston - Chief Financial Officer ... Read th...

2026-02-26 18:25:34 ET Image source: The Motley Fool. Thursday, Feb. 26, 2026 at 4:45 p.m. ET Progyny (NASDAQ:PGNY) ended fiscal 2025 with record revenue and adjusted EBITDA, with both measures surpassing guidance midpoints by meaningful margins. The company’s diversi...

2026-02-26 16:10:25 ET More on Progyny Progyny, Inc. (PGNY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Progyny, Inc. (PGNY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Progyny Q4 2025 Earnings Preview Seekin...

Reports Revenue of $318.4 Million, Reflecting Fourth Quarter Growth of 6.7% and 10% for the Full Year Generated Record $210.2 Million in Full Year Operating Cash Flow Returned Value to Shareholders Through Repurchase of Approximately 6.5 Million Shares To Date Under Recent Authorization Issues Fi...

Evertec Inc. (EVTC) is expected to report $0.81 for Q4 2025 BioCryst Pharmaceuticals Inc. (BCRX) is expected to report $0.06 for Q4 2025 FTI Consulting Inc. (FCN) is expected to report $1.38 for Q4 2025 Arbe Robotics Ltd. (ARBE) is expected to report $-0.1 for Q4 2025 Aclaris Ther...